Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
F. Sahin (Istanbul, Turkey), A. Aslan (Istanbul, Turkey), Ç. Koç Karaçar (Istanbul, Turkey). Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia?. 4541

Member's Comments

No comment yet.

Related content which might interest you: Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 The clinical diagnosis and treatment of COPD Source: International Congress 2019 – An update on chronic obstructive pulmonary disease Year: 2019 The diagnosis and treatment of chronic cough patients Source: Eur Respir J 2005; 26: Suppl. 49, 300s Year: 2005 The role of inflammatory parameters in the diagnosis and management of patients with community-acquired pneumonia Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients Source: Eur Respir J 2011; 38: 643-648 Year: 2011 Patients’ adherence to chronic treatment of pulmonary diseases Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Non-invasive inflammatory markers can predict diagnosis, severity and stability of paediatric asthma Source: Eur Respir J 2006; 28: Suppl. 50, 122s Year: 2006 Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study Source: Annual Congress 2011 - COPD management Year: 2011 Benralizumab efficacy in patients with uncontrolled eosinophilic asthma by age at diagnosis Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Time to move from prognostication to diagnosis and treatment of heart disease in acute exacerbation of COPD Source: Eur Respir J, 49 (6) 1700912; 10.1183/13993003.00912-2017 Year: 2017 Duration of therapy in hospitalised patients with CAP Source: Annual Congress 2007 - An international perspective of the management of hospitalised patients with community-acquired pneumonia Year: 2007 1-year prospective study in severe COPD patients: marker of inflammation, lung function and radiologic evaluation Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007 Can we personalize COPD treatment by exacerbation frequency and severity? Three years of follow-up Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Exacerbation types by COPD severity; risk of hospitalisation by patients not seeking treatment Source: Eur Respir J 2003; 22: Suppl. 45, 353s Year: 2003 When will exhaled biomarkers influence diagnosis and follow-up of patients with respiratory disease? Source: International Congress 2015 – The next generation of lung function tests Year: 2015 Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Diagnosis confirmation and staging in patients hospitalized with diagnosis of COPD in a general hospital with adequate resources Source: Annual Congress 2013 –COPD treatment Year: 2013 Treatment strategies for patients with complex chronic comorbidities Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases Year: 2006